SI
RYTM icon

Sofinnova Investments’s Rhythm Pharmaceuticals RYTM Stock Holding History

Sofinnova Investments’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-225,000
Closed -$14.2M – 72
2025
Q2 		$14.2M Buy
+225,000
New +$13.8M 0.87% 34

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Sofinnova Investments's RYTM Position: Q1 2026 in Review

Sofinnova Investments increased its Rhythm Pharmaceuticals (RYTM) stake by 66% in Q1 2026, buying an estimated $17.4M and bringing the position to 450,096 shares worth $39.1M. The position accounts for 1.49% of the portfolio, ranked #22.

Sofinnova Investments first reported a position in RYTM in Q2 2018 and has held it in 10 quarters since. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • Sofinnova Investments held 450,096 shares of Rhythm Pharmaceuticals worth $39.1M as of Q1 2026.
  • Sofinnova Investments bought 178,702 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $17.4M.
  • Rhythm Pharmaceuticals made up 1.49% of Sofinnova Investments's portfolio in Q1 2026, its #22 holding.
  • Sofinnova Investments first reported a position in Rhythm Pharmaceuticals in Q2 2018 and has held it in 10 quarters since.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Sofinnova Investments's 13F filing for Q1 2026, filed 15 May 2026.